NRD
VNDA icon

Nebula Research & Development’s Vanda Pharmaceuticals VNDA Stock Holding History

Nebula Research & Development’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26,736
Closed -$113K – 1016
2023
Q4 		$113K Buy
+26,736
New +$108K 0.03% 601

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's VNDA Position: Q1 2024 in Review

Nebula Research & Development sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 26,736 shares — an estimated $113K sold.

Nebula Research & Development first reported a position in VNDA in Q4 2023 and held it in 1 quarter. The position peaked at $113K in Q4 2023. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

  • Nebula Research & Development reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Nebula Research & Development sold 26,736 Vanda Pharmaceuticals shares in Q1 2024, an estimated $113K.
  • Nebula Research & Development first reported a position in Vanda Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Nebula Research & Development's Vanda Pharmaceuticals position peaked at $113K in Q4 2023.
  • 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on Nebula Research & Development's 13F filing for Q1 2024, filed 15 May 2024.